Capricor Therapeutics, Inc.
NASDAQ:CAPRBiotechnology
-$0.14 today
- Market cap
- $465.03M
- Beta
- 0.37
- P/E (TTM)
- -13.9
- EPS (TTM)
- -$2.00
Volume 8.33M
Average 1.08M
CAPR Total Current Liabilities
All obligations due within one year.
Capricor Therapeutics, Inc.NASDAQ: CAPR
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 50.6% from a year ago
Total current liabilities stood at $33.64M at the end of Q1 FY2026, up 50.6% from a year earlier and down 6.1% from the prior quarter. Over 3 fiscal years it compounded at +15.0% a year.
Context
- Total current liabilities amounted to 10.3% of total assets at the end of Q1 FY2026, down 4.2 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +50.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 35.84M USD
- Year-over-year change
- +70.4%
- 4-year CAGR
- +71.6%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 35.84M | +70.4% |
| FY2024 | 2024-12-31 | 21.03M | -32.8% |
| FY2023 | 2023-12-31 | 31.27M | +32.6% |
| FY2022 | 2022-12-31 | 23.59M | +470.6% |
| FY2021 | 2021-12-31 | 4.13M | — |
Total Current Liabilities vs competitors
How CAPR compares with its peers on the latest reported figures
- CAPR's Mar 2026 total current liabilities of $33.64M is the 7th highest of the 10 companies compared; the peer median is $78.03M.
- Its year-over-year change of +50.6% is the 3rd highest of 10, against a peer median of +4.1%.
- Total current liabilities amounts to 10.3% of total assets for CAPR, versus a peer median of 8.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $771.07M | +22.8% | +33.6% | 23.7% | |
| Mar 2026 | $499.16M | -17.6% | +20.9% | 15.7% | |
| Sep 2026 | $435.29M | -51.8% | +35.9% | 14.9% | |
| Sep 2026 | $144.11M | +565.7% | +18.2% | 8.1% | |
| Jun 2026 | $78.03M | +88.1% | +21.7% | 7.8% | |
| Mar 2026 | $49.83M | -43.0% | +10.0% | 8.5% | |
| Mar 2026 | $33.64M | +50.6% | +15.0% | 10.3% | |
| Mar 2026 | $30.28M | +5.2% | +14.1% | 7.2% | |
| Mar 2026 | $19.2M | +4.1% | +3.6% | 5.7% | |
| Mar 2026 | $8.96M | -56.1% | -12.4% | 5.7% | |
| Peer median (excluding CAPR) | $78.03M | +4.1% | +18.2% | 8.1% | |
Competitors are the stored peer set for CAPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 34.89M | 9.6M | 14.69M | 11.29M | 287.85M |
| Short-term Investments | 0 | 31.82M | 24.79M | 140.23M | 30.28M |
| Net Receivables | 391.75K | 547.58K | 10.37M | 10.37M | 59.17K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 919.89K | 0 | 0 | 0 |
| Total Current Assets | 36.44M | 42.89M | 50.86M | 163.39M | 322.94M |
| Property, Plant & Equipment (Net) | 4.62M | 6.94M | 7.61M | 6.87M | 18.31M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 275.72K | 268.17K | 268.17K | 221.7K | 14.7M |
| Total Non-current Assets | 4.89M | 7.21M | 7.88M | 7.1M | 33.01M |
| Total Assets | 41.33M | 50.09M | 58.73M | 170.48M | 355.95M |
| Account Payables | 3.72M | 4.83M | 6.24M | 3.28M | 1.65M |
| Short-term Debt | 417.63K | 682.04K | 749.11K | 834.8K | 3.62M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 17.98M | 24.27M | 12M | 12M |
| Other Current Liabilities | 0 | 0 | 0 | 2.36M | 11.85M |
| Total Current Liabilities | 4.13M | 23.59M | 31.27M | 21.03M | 35.84M |
| Long-term Debt | 3.38M | 3.38M | 3.38M | 3.38M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 9.47M | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 5.83M | 14.72M | 4.86M | 3.99M | 14.32M |
| Total Liabilities | 9.96M | 38.31M | 36.13M | 25.02M | 50.16M |
| Common Stock | 24.19K | 25.24K | 31.15K | 45.58K | 57.37K |
| Retained Earnings | (108.06M) | (137.08M) | (159.37M) | (199.83M) | (304.88M) |
| Accumulated OCI | 0 | 105.24K | 235.81K | 1.03M | 283.15K |
| Other Stockholders Equity | (0) | 0 | 1 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 31.37M | 11.79M | 22.6M | 145.46M | 305.79M |
| Total Debt | 6.25M | 5.94M | 5.61M | 4.83M | 17.94M |
| Net Debt | (28.64M) | (3.67M) | (9.08M) | (6.46M) | (269.9M) |
Capricor Therapeutics, Inc.
NASDAQ:CAPR
Intrinsic Alpha fair value
Locked
Current Price
$8.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.